Induced Pluripotent Stem Cells Production Market to grow by USD 1.55 billion

Technavio’s latest offering Induced Pluripotent Stem Cells Production Market report provides a detailed analysis on the competitive scenario and the market growth across various regions. The induced pluripotent stem cells production market value is expected to grow by USD 1.55 billion, progressing at a CAGR of 11.39% from 2021 to 2026. 33% of the market’s growth will originate from North America. The US is a key market for induced pluripotent stem cells production in North America. 

Attractive Opportunities in Induced Pluripotent Stem Cells Production Market by End-user and Geography - Forecast and Analysis 2022-2026
Attractive Opportunities in Induced Pluripotent Stem Cells Production Market by End-user and Geography – Forecast and Analysis 2022-2026

For more insights on Induced Pluripotent Stems Cells Production Market – Download a free sample now!

Market Dynamics

The market is driven by factors such as the technological advancements in manufacturing, the rising prevalence of several chronic disorders such as diabetes, heart disease, stroke, and cancer, and the rising financial assistance by governments. However, the lack of awareness is hindering market growth.

Company Profiles

The induced pluripotent stem cells production market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The induced pluripotent stem cells production market report provides complete insights on key vendors including Applied StemCell Inc., Axol Biosciences Ltd., Evotec SE, Fate Therapeutics Inc., Hitachi Ltd., LIFE & BRAIN GmbH, Lonza Group Ltd., Merck KGaA, REPROCELL Inc., and Thermo Fisher Scientific Inc.

Few Companies with Key Offerings

  • Applied StemCell Inc. – The company is involved in offering mouse embryonic stem cells, mouse iPSCs and cell lines derived from integration-free iPSCs using feeder-free culture protocols. 
  • Axol Biosciences Ltd. – The company is involved in offering induced pluripotent stem cells by using edge reprogramming technologies such as non-integrating episomal or Sendai virus reprogramming. 
  •  Evotec SE – The company is involved in offering iPSC-based, off-the-shelf cell therapies with long-lasting efficacy.

Competitive Analysis

The competitive scenario provided in the induced pluripotent stem cells production market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Segmentation

  • By End-user, the market is classified as Hospitals, Research Institutes, Biotechnology Companies, and Others. The induced pluripotent stem cells production market share growth by the hospitals segment has been significant. 
  • By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market.

Related Reports –
Hematopoietic Stem Cells Transplantation Market  –The hematopoietic stem cells transplantation (HSCT) market has the potential to grow by USD 1.99 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 6.16%. Download a free sample now!

Allogeneic Stem Cells Market  -The global allogeneic stem cells market size has the potential to grow by USD 1.24 billion during 2020-2024, and the market’s growth momentum will accelerate during the forecast period. Download a free sample now!

Induced Pluripotent Stem Cells Production Market Scope
Report CoverageDetails
Page number120
Base year2021
Forecast period2022-2026
Growth momentum & CAGRAccelerate at a CAGR of 11.39%
Market growth 2022-2026USD 1.55 billion
Market structureFragmented
YoY growth (%)10.14
Regional analysisNorth America, Europe, Asia, and ROW
Performing market contributionNorth America at 33%
Key consumer countriesUS, China, UK, Germany, and Japan
Competitive landscapeLeading companies, competitive strategies, consumer engagement scope
Companies profiledApplied StemCell Inc., Axol Biosciences Ltd., Evotec SE, Fate Therapeutics Inc., Hitachi Ltd., LIFE & BRAIN GmbH, Lonza Group Ltd., Merck KGaA, REPROCELL Inc., and Thermo Fisher Scientific Inc.
Market DynamicsParent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period
Customization purviewIf our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

Related Links

http://www.technavio.com

Leave a Reply

Your email address will not be published. Required fields are marked *